Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

9.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.3K
Coagulation01:06

Coagulation

1.1K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

13.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

204
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Vein Thrombosis: A Narrative Review.

Diagnostics (Basel, Switzerland)·2026
Same author

DIC in pregnancy: lessons from an international registry of the International Society for Thrombosis and Hemostasis: Communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Thrombosis research·2026
Same author

Where Is the 'Oma' in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology.

EJHaem·2026
Same author

Can machine learning identify inherited causes of thrombocytopenia? A feasibility study.

British journal of haematology·2026
Same author

Controversies in thromboprophylaxis: a focus on nonsurgical patients.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

Coagulopathy in COVID-19.

Toshiaki Iba1, Jerrold H Levy2, Marcel Levi3

  • 1Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Journal of Thrombosis and Haemostasis : JTH
|June 20, 2020
PubMed
Summary
This summary is machine-generated.

COVID-19 infection often causes coagulopathy, characterized by blood clot formation. Coagulation tests can help identify severe cases, with organ dysfunction being the primary clinical feature.

Keywords:
COVID-19anticoagulantcoagulopathycoronavirusdisseminated intravascular coagulation

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.3K

Related Experiment Videos

Last Updated: Dec 18, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.3K

Area of Science:

  • Hematology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • The COVID-19 pandemic presents significant global health challenges.
  • Severe COVID-19 cases frequently exhibit coagulopathy, marked by disseminated intravascular coagulation (DIC)-like intravascular clot formation.
  • Understanding COVID-19-associated coagulopathy is crucial for managing severe illness.

Purpose of the Study:

  • To explore the utility of coagulation tests in distinguishing severe COVID-19 cases.
  • To characterize the clinical presentation and hemostatic biomarker changes in COVID-19-associated coagulopathy.
  • To compare COVID-19 coagulopathy with sepsis-associated coagulopathy/DIC.

Main Methods:

  • Analysis of clinical presentations in severely ill COVID-19 patients.
  • Evaluation of hemostatic biomarkers, including D-dimer and fibrin/fibrinogen degradation products.
  • Comparison of coagulation parameters (prothrombin time, activated partial thromboplastin time, antithrombin activity, platelet count) with bacterial sepsis-associated coagulopathy/DIC.

Main Results:

  • COVID-19-associated coagulopathy primarily manifests as organ dysfunction, with less frequent bleeding events.
  • Elevated D-dimer and fibrin/fibrinogen degradation products indicate significant fibrin formation.
  • Compared to sepsis-associated coagulopathy/DIC, COVID-19 shows less frequent prolongation of PT/aPTT, decreased antithrombin activity, and lower incidence of thrombocytopenia.
  • Potential mechanisms include dysregulated immune responses, cytokine storms, lymphocyte cell death, hypoxia, and endothelial damage.

Conclusions:

  • Coagulation tests may aid in identifying severe COVID-19.
  • COVID-19-associated coagulopathy differs from sepsis-induced coagulopathy/DIC in its clinical and laboratory features.
  • Further research is needed to elucidate the exact mechanisms and address uncertainties regarding thrombosis incidence and optimal anticoagulation strategies in COVID-19.